FDA greenlights Eli Lilly’s Zepbound: A game-changer in weight loss medication landscape

USA — The Food and Drug Administration (FDA) has granted approval to Eli Lilly’s Zepbound, a potent medication for weight loss targeting adults grappling with obesity or overweight conditions alongside related health issues.

This approval marks a significant milestone in addressing the burgeoning demand for effective weight loss treatments in the face of escalating obesity rates in the United States.

Zepbound, originally known as Mounjaro for Type 2 diabetes treatment, belongs to the class of GLP-1 agonists, a category of medications revolutionizing the approach to obesity.

The demand for these drugs, including competitors like Novo Nordisk’s Wegovy, has surged, surpassing the supply capacities of manufacturers like Lilly.

John Sharretts, head of the FDA’s division for diabetes, lipid disorders, and obesity, emphasized the critical need Zepbound addresses, stating, “Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke, and diabetes.”

A weighty issue in the U.S.

National Institutes of Health statistics reveal that nearly one in three adults in the U.S. is overweight, with over 40% experiencing obesity.

The correlation between excessive weight and health conditions such as diabetes and heart disease underscores the urgency of developing effective treatments like Zepbound.

GLP-1 agonists, activating a gut hormone receptor, are believed to work by reducing appetite and slowing gastric emptying.

While early versions had modest effects, newer drugs like Wegovy, Mounjaro, and Novo’s Ozempic offer enhanced blood sugar control and substantial weight loss, positioning GLP-1 therapies as dominant players in metabolic disease treatment.

Beyond weight loss

Novo’s trial results indicate that Wegovy might prevent heart-related complications, a potential game-changer for insurers considering coverage.

Additionally, Ozempic has shown promise in treating kidney disease, broadening the therapeutic scope of GLP-1 agonists beyond weight and blood sugar control.

Though Zepbound and Wegovy haven’t undergone direct comparison, Lilly’s data suggests potential advantages in greater weight loss.

In clinical trials, Wegovy-treated participants experienced weight loss ranging from 10% to 16%, while Zepbound demonstrated a substantial 12% to 18% reduction in body weight.

While both drugs carry black box warnings for the risk of thyroid tumors, Zepbound received an additional safety warning for severe gastrointestinal disease, distinguishing it from Wegovy.

While celebrating Zepbound’s approval, the FDA has issued safety warnings, particularly for severe gastrointestinal disease.

This caution, absent in Wegovy’s labeling, adds a layer of complexity to the drugs’ comparative safety profiles.

As the cardiovascular data for Wegovy is set to be presented at the American Heart Association’s annual meeting, the industry eagerly awaits insights into the potential cardiovascular benefits of these groundbreaking medications.

Despite safety concerns, Wegovy sales have skyrocketed, reaching 21.7 billion Danish krone (US$3.1 billion) over the first nine months of the year.

Lilly’s Competitive edge and pricing strategy

As Eli Lilly anticipates strong demand for Zepbound, the company has positioned itself competitively in the market. Zepbound’s list price is set at US$1,059 per month, approximately 20% lower than Novo’s rival drug, Wegovy.

The market success of Mounjaro, contributing US$3 billion in sales during the first nine months of the year, has propelled Lilly to the forefront of the pharmaceutical industry with a market value of nearly US$600 billion.

Looking beyond the U.S., Eli Lilly has sought approval for Zepbound in Europe, China, the U.K., and several other countries.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.